Karyopharm Therapeutics is conducting this clinical trial, a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in patients with relapsed/refractory multiple myeloma. The study is currently open and accepting approximately 116 patients. The trial will take place at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee. This is an interventional trial and will be used to treat your myeloma. XP01 is a nuclear transport protein that is over-expressed in myeloma and is an essential protein for myeloma growth. Inhibiting or stopping this protein enables myeloma cell death, even in heavily pre-treated patients. This new drug is the second inhibitor to be developed by Karyopharm Therapeutics. Their other drug, Selinexor, is now also in clinical trials. In leukemia studies, this new drug, KPT-8602, has been shown to have better tolerability than Selinexor. To be considered for the trial, patients must exhibit symptomatic relapsed or refractory disease requiring current treatment. They must also have been previously treated with at least three or more prior lines of therapy that include at least one of each of the following: alkylating agent, immunomodulatory drug, proteasome inhibitor, and a steroid. Patients must be refractory to their most recent anti-cancer regimen. For more information about this study, visit SparkCurest link here: Spark Cures: Study of Safety, Tolerability & Efficacy of KPT-8602 in Patients With Relapsed/Refractory Myeloma
about the author
Lizzy Smith was diagnosed with myeloma in 2012 at age 44. Within days, she left her job, ended her marriage, moved, and entered treatment. "To the extent I'm able, I want to prove that despite life's biggest challenges, it is possible to survive and come out stronger than ever," she says.